PMN (ProMIS Neurosciences) Institutional Ownership: 68.50% (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PMN ProMIS Neurosciences Inc PMN
34 GF Score
Price $15.23
! 2 Warning Signs
View Full Analysis

What is ProMIS Neurosciences Institutional Ownership?

ProMIS Neurosciences PMN +14.47% 34 Institutional Ownership is 68.50% as of Jul. 17, 2026. GuruFocus rates PMN with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, ProMIS Neurosciences's institutional ownership is 68.50%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, ProMIS Neurosciences's Insider Ownership is 4.19%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, ProMIS Neurosciences's Float Percentage Of Total Shares Outstanding is 99.37%.

ProMIS Neurosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for ProMIS Neurosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProMIS Neurosciences Institutional Ownership Chart

ProMIS Neurosciences Historical Data

The historical data trend for ProMIS Neurosciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.06 0.82 0.64 0.64 0.42 0.02 0.06 0.06 0.06 0.06
PMN
34GF Score
ProMIS Neurosciences Inc PMN
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProMIS Neurosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 68.50% mean?
ProMIS Neurosciences (PMN) has a Institutional Ownership of 68.50% as of Jul. 17, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ProMIS Neurosciences and its competitors.
Is ProMIS Neurosciences' Institutional Ownership too high?
ProMIS Neurosciences' current Institutional Ownership is 68.50%. Overall, ProMIS Neurosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Institutional Ownership compare to BMEA and ANIX?
ProMIS Neurosciences' Institutional Ownership of 68.50% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on ProMIS Neurosciences and its competitors. ProMIS Neurosciences's current Institutional Ownership is 68.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Institutional Ownership of 68.50%. The current Institutional Ownership is 68.50%. ProMIS Neurosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Institutional Ownership is 68.50% as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProMIS Neurosciences Business Description

Other Exchanges 23J:Germany
Address 1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
34GF Score

Get the complete analysis for PMN

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.23
Price